Tezspire (AstraZeneca, Amgen) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Tezspire Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The "Tezspire Market Global Report 2026" is an essential resource designed to equip strategists, marketers, and senior management with critical insights into the dynamic tezspire market. This comprehensive document addresses the continuous growth of the market and outlines upcoming trends expected to shape the landscape over the next decade.
The growth observed in the historic period was primarily influenced by an increasing prevalence of severe asthma, advancements in monoclonal antibody development, and a growing adoption of biologics in respiratory medicine. These factors, along with the expansion of specialty respiratory clinics and improved asthma phenotype diagnostic classification, contributed to market expansion.
Looking to the forecast period, growth is expected to be driven by the expansion of biologic indications and increasing demand for personalized respiratory therapies. Rising investments in immunology drug development and a growing focus on early intervention strategies are set to foster this growth. Additionally, the expansion of advanced asthma treatment guidelines is anticipated to support market progress. Key trends include increased adoption of targeted biologic therapies, rising use of TSLP inhibitors in respiratory care, and an enhanced focus on severe asthma management.
The increasing prevalence of asthma is projected to drive the Tezspire market's growth further. Factors such as environmental pollution, lifestyle changes, and heightened exposure to allergens are linked to rising asthma cases. Tezspire, a targeted biologic therapy, effectively manages severe asthma by inhibiting proteins involved in airway inflammation, providing relief for patients unresponsive to standard treatments. For example, the National Asthma Council in Australia reported 474 asthma-related deaths in 2023, indicating a persistent trend in asthma-related mortality.
The surge in clinical trials is another significant factor expected to bolster the Tezspire market. These trials are vital in demonstrating Tezspire's safety and efficacy, influencing its approval for severe asthma treatment. For instance, the Association of the British Pharmaceutical Industry reported an increase in UK industry-sponsored clinical trials from 411 in 2022 to 426 in 2023.
Companies in the Tezspire market are actively seeking regulatory approvals for broader indications, with a focus on conditions like asthma. Notably, AstraZeneca plc, in partnership with Amgen Inc., received approval in February 2023 for self-administration of Tezspire via a pre-filled pen for severe asthma patients aged 12 and older. Supported by the PATHFINDER clinical trial program, which showed high self-administration success, Tezspire is distinctive as the first biologic for severe asthma not limited by phenotype or biomarker status.
Major players like AstraZeneca plc and Amgen Inc. dominate the Tezspire market, with North America being the largest region as of 2025. High-impact tariffs are affecting the market by increasing costs associated with imported biologic manufacturing equipment and distribution logistics. This has prompted regional manufacturing expansion and supply chain optimizations, especially in North America and Europe.
The Tezspire market research reports provide comprehensive insights, covering market statistics, regional shares, competitor analysis, and future trends. This biologic therapy, which targets thymic stromal lymphopoietin, is utilized for treating severe asthma and related conditions, aiding in inflammation reduction and breathing improvement.
Tezspire primarily addresses conditions such as asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis, distributed through hospital and retail pharmacies and online platforms. The market includes the sale of monoclonal antibodies, vaccines, and fusion proteins, representing 'factory gate' values.
Report Scope:
Global Tezspire Market Trends and Strategies
For more information about this report visit https://www.researchandmarkets.com/r/goooch
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.